Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma-Reference-Cited by-同舟云学术

Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma

Published:2023-02 Issue:2 Volume:173 Page:280-288
ISSN:0039-6060
Container-title:Surgery
language:en
Short-container-title:Surgery

Author:

Choi Sung Hoon^ORCID,Kang Incheon^ORCID,Lee Sung Hwan,Kang Beodeul,Cheon Jaekyung,Kim Dae Jung,Kim Gwangil,Kwon Chang-Il,Ko Kwang Hyun^ORCID,Chon Hong Jae

Funder

Ministry of Science, ICT and Future Planning

National Research Foundation of Korea

Publisher

Elsevier BV

Subject

Surgery

Reference21 articles.

1. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N Engl J Med,2010

2. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan;Okusaka;Br J Cancer,2010

3. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma;Jarnagin;Ann Surg,2001

4. Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma;Jung;World J Gastroenterol,2017

5. Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma;Sumiyoshi;World J Surgery,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of distal cholangiocarcinoma with arterial involvement: Systematic review and case series on the role of neoadjuvant therapy;World Journal of Gastrointestinal Surgery;2024-08-27

2. Efficacy and biomarker analysis of second‐line nab‐paclitaxel plus sintilimab in patients with advanced biliary tract cancer;Cancer Science;2024-04-18

3. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study;BMC Cancer;2024-04-08